Mass Torts Made Perfect Webinar

Jan 16, 2023 | 0 comments

We attended another webinar put on by the good people of Mass Torts Made Perfect and Levin Papantonio Rafferty, this time about the Hair Relaxer litigation.

This is one of the bigger cases we are working as we start 2023. While there isn’t an MDL as of today, the expectation is that one will be created shortly after oral arguments on centralization in late January.

Due to the similarly situated plaintiffs from across the country, MDL treatment makes sense, and we’re quite sure the JPML will agree.

We’d like to take just a moment at the outset and say a big thanks to the people putting on these seminars. They are informative and helpful for every plaintiff attorney, including staff.

Deep Pockets

The defendants have deep pockets, at least some of them. L’Oreal and Revlon are the big ones, but there are others (Soft Sheen, Godrej Consumer Products, Strength of Nature, Dabur USA, and Namaste Labs).

It’s worth noting that Revlon is currently going through Chapter 13 Bankruptcy, so that may prevent or delay some aspects of the case.

Brand loyalty is not especially strong with these products, as they are used regularly and often. Typically, price is the most important factor. So, locating the bestdefendants may be one of the biggest challenges in prepping a case. 

Demographic Concerns

This case is especially delicate due to the racial makeup of the plaintiff class, and plaintiff attorneys would be wise to be careful in their marketing.

The plaintiffs in this litigation will be almost exclusively African American. In fact, the very nature of African American hair and its importance to the culture makes this case especially sensitive.

Hair has always had a very important role in African cultures, and that importance continued, maybe even increased, with the slave trade and African American life.  

One recommendation we make is to utilize attorneys in your offices that can connect with this demographic.

In a competitive marketplace, this may be your most important decision. After that, however, intake will also be incredibly important.  

Intake

Your first question should be about the caller’s background. If they are African American, Latina, or Indian, they potentially fall in line with the rest of the intake requirements. Your marketing should target these demographics.

Use of these products tends to become part of a regular routine, going on for yearsor longer.

The chemicals in the product seeps into the scalp and enters the bloodstream, affecting the endocrine system. The cancers associated with these products are all Estrogen based cancers.

A good plaintiff will have used these products frequently, and this may also be a key question on intake. At a minimum, a plaintiff should be able to prove that they used one of the products in question at least four times in a year.  

Long-term is the better, and the best potential clients will be able to prove use over at least 2-5 years of continual use. More is better for the litigation, but a minimum of four times in a year needs to be proven.

When talking to a potential client, try to obtain the specific product used, the datesof use, and the location of purchase.  

If no direct evidence is available, consider prepping a strong affidavit based on the potential client’s specific information, maybe even including an affidavit from a hairdresser.

Other evidence that may help include photos of the client’s hair in a straightened state, product boxes in the background, and anything that can support use.

A plaintiff’s case becomes weaker if it has been more than 20 years since the last product use. 

Diagnosis

As is the case with most of these types of cases, a strong diagnosis may also be a gatekeeper to the MDL.

As of writing, a plaintiff will need to show a diagnosis of

  1. Uterine/endometrial cancer
  2. Ovarian cancer
  3. Uterine fibroids.  

A diagnosis more than 10 years old weakens the case, so make sure that you get a new diagnosis if your client comes in with an especially old diagnosis.  

One other concern is when a potential plaintiff has ever tested positive for a BRCAgene mutation test.

But beyond that, a strong diagnosis should guide a plaintiff lawyer how to proceed. 

Important Case for 2023

2023 is going to be a big year for this case, and even though it has not been centralized as an MDL yet, it almost certainly will be.

Thanks again to the people at MPTP and Levin Papantonio Rafferty for hosting the webinar. These are great sources of information, and we can’t recommend them highly enough.  

Best Case Leads Celebrates Sixth Consecutive Year on Inc. 5000 List of Fastest-Growing Private Companies in America

Aug 19, 2025 | Press Releases Houston, TX, August 18, 2025 — Best Case Leads, a pioneering leader in legal lead generation, proudly announces its sixth consecutive recognition on the prestigious Inc. 5000 fastest-growing private companies in...

Baby Formula Litigation, NEC Claims, and the Evolving Landscape of Mass Torts

By Fadi Agour, J.D. Families of premature infants who developed necrotizing enterocolitis (NEC) after being fed cow–milk–based formula products like Similac and Enfamil continue to pursue justice in both state and federal courts. Recent...

Mass Tort Landscape 2025: Key Cases, Trends & Strategic Opportunities

The mass tort landscape is evolving rapidly, with new cases gaining momentum and established litigations reaching critical phases. For law firms and legal marketers, timing is everything—success hinges on anticipating trends, securing high-value claimants early, and...

Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort

The pharmaceutical litigation landscape has seen its share of blockbuster cases—from opioid multidistrict litigations to the ongoing Paraquat Parkinson’s claims. But a new California lawsuit (Brown v. Johnson & Johnson et al.) could revive two legacy antipsychotics...

Mass Torts in 2025: A Legal Landscape in Flux

As 2025 unfolds, the world of mass tort litigation shows no signs of slowing down. From pharmaceutical giants to tech behemoths, corporations across industries are facing an unprecedented wave of lawsuits that could reshape their futures. With judges issuing critical...

The PFAS Contamination Crisis: A Deep Dive into the Mass Tort Litigation and Its Implications

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a focal point of environmental and public health concerns in the United States. These synthetic chemicals, used for their water, heat, and grease-resistant properties,...

The Ultra-Processed Foods Lawsuit: A Must-Know Update for Mass Tort Lawyers

Ultra-processed foods (UPFs) have become a cornerstone of modern diets, but their convenience comes at a cost. As consumption of these foods has skyrocketed, so too have the alarming health complications linked to them, including obesity, diabetes, heart disease, and...

Understanding the BioZorb Litigation: A Growing Legal Battle for Plaintiff Attorneys

What is BioZorb? The BioZorb litigation is shaping up to be one of the most significant legal challenges of 2025, presenting a unique opportunity for plaintiff attorneys nationwide. This case revolves around a medical device designed to aid breast cancer patients but...

The Role of Technology in Optimizing Workers’ Compensation Lead Generation

The process of generating and managing workers' compensation leads has undergone a significant transformation with the advent of technology. Modern tools and software solutions are now indispensable in streamlining operations, improving lead quality, and enhancing...

How to Build a Referral Network for Mass Tort Cases

Mass tort cases often involve a large number of claimants seeking justice for harm caused by a common defendant, such as pharmaceutical companies or manufacturers. For attorneys specializing in these cases, building a robust referral network can significantly boost...

Ready to Start Receiving Qualified Leads?

Get exclusive, real-time legal leads delivered to your firm.

Get Started